Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia

Dear Editor, Diagnostic bone marrow (BM) DNA and matched plasma-derived circulating tumour DNA (ctDNA) demonstrated excellent correlations in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML),1–4 and dynamic ctDNA monitoring contributes to predict relapse in MDS and AML patients unde...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational medicine 2023-07, Vol.13 (7), p.e1349-n/a
Main Authors: Zhou, Xinping, Lang, Wei, Mei, Chen, Ren, Yanling, Ma, Liya, Jiang, Lingxu, Ye, Li, Xu, Gaixiang, Luo, Yingwan, Liu, Lixia, Cao, Shanbo, Qin, Jiayue, Tong, Hongyan
Format: Article
Language:English
Subjects:
Biomarkers
Bone marrow
Circulating Tumor DNA - genetics
Clinical outcomes
Cloning
Humans
Letter to the Editor
Leukemia
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - pathology
Medical prognosis
Mutation
Myelodysplastic syndromes
Myelodysplastic Syndromes - diagnosis
Myelodysplastic Syndromes - genetics
Patients
Plasma
Stem cell transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dear Editor, Diagnostic bone marrow (BM) DNA and matched plasma-derived circulating tumour DNA (ctDNA) demonstrated excellent correlations in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML),1–4 and dynamic ctDNA monitoring contributes to predict relapse in MDS and AML patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).5 However, few researches are reported on the application of ctDNA dynamic monitoring assessments during the whole disease course in MDS and AML.1 Here, we assessed the feasibility and utility of ctDNA as a novel and minimally invasive biomarker based on targeted next-generation sequencing (NGS) to monitor treatment outcome, track clonal evolution and predict survival. To investigate the prognostic differences between mean ctDNA VAF and mean ctDNA concentration change from post- to pre-treatment, we compared the discrimination ability of the prognostic model with the concordance index (C-index). SEE PDF] In summary, our study revealed that serial plasma-derived ctDNA assessments can reflect treatment response, survival, and clonal evolution in adult MDS and AML as a minimally invasive method, which warrant the prospective use of ctDNA as a biomarker in disease monitoring.
ISSN:2001-1326
2001-1326
DOI:10.1002/ctm2.1349